SCM
VRTX icon

SCS Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

SCS Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-416
Closed -$202K – 566
2025
Q1 		$202K Buy
+416
New +$194K ﹤0.01% 491

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCS Capital Management's VRTX Position: Q2 2025 in Review

SCS Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 416 shares — an estimated $202K sold.

SCS Capital Management first reported a position in VRTX in Q1 2025 and held it in 1 quarter. The position peaked at $202K in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • SCS Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • SCS Capital Management sold 416 Vertex Pharmaceuticals shares in Q2 2025, an estimated $202K.
  • SCS Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • SCS Capital Management's Vertex Pharmaceuticals position peaked at $202K in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on SCS Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.